ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)

Ardelyx shareholders lost roughly $0.87 per share in a single session on August 7, 2026, when ARDX closed at $4.00 -- down 17.86% -- after the Company withdrew its long-term $750 million XPHOZAH revenue target.

NEW YORK--(BUSINESS WIRE)--Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's second quarter report. If you held ARDX shares and lost money, you are encouraged to submit your loss information for review. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The damage came alongside numbers the Company itself called records. Ardelyx reported Q2 2026 product revenue of $118.1 million, up 31% year over year, with IBSRELA at $86.2 million (+33%) and XPHOZAH at $31.9 million (+27%). EPS was approximately $(0.07). Shares still fell nearly 18% the following session.

Alongside those results, Ardelyx withdrew its previously stated long-term $750 million XPHOZAH revenue target, while maintaining 2026 XPHOZAH guidance of $110 million to $120 million. Conversely, it maintained its long-term $1 billion target for IBSRELA while cutting revenue expectations from at least $410 to no more than $370 million. Shares fell nearly 18% on the news.

Investors who purchased Ardelyx shares and suffered a loss may have their potential recovery evaluated at no cost, or call Joseph E. Levi, Esq. at [phone].

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the ARDX Investigation

Q: How much did ARDX stock drop? A: Shares fell approximately 17.86%, a decline of roughly $0.87 per share, closing at $4.00 on August 7, 2026 after Ardelyx reported second quarter results and withdrew its long-term $750 million XPHOZAH revenue target. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: Who is eligible to participate in the ARDX investigation? A: Investors who purchased ARDX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: When did Ardelyx allegedly mislead investors? A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do ARDX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my ARDX shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ARDX and sold at a loss may still participate in the investigation.

Q: What if my ARDX losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.